Biodexa Pharmaceuticals Plc（BDRX）美股招股说明书 F-1（2026-07-30修订版）（英文版）（47页）.pdf

1、 AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON JULY 30,2026Registration No.333-297473 UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549 Pre-Effective Amendment No.1toFORM F-1REGISTRATION STATEMENTUNDERTHE SECURITIES ACT OF 1933Biodexa Pharmaceuticals PLC(Exact name of reg

2、istrant as specified in its charter)England and Wales2834Not Applicable(State or Other Jurisdiction ofIncorporation or Organization)(Primary Standard IndustrialClassification Code Number)(IRS EmployerIdentification No.)1 Caspian PointCaspian WayCardiff,CF10 4DQ,United KingdomTel:+44 29 20480 180(Add

3、ress,including zip code,and telephone number,including area code,of registrants principal executive offices)Donald J.PuglisiPuglisi&Associates850 Library Ave.,Suite 204Newark,Delaware 19711Tel:(302)738-6680(Name,address,including zip code,and telephone number,including area code,of agent for service

4、)Copies of communications to:Jason S.McCaffreyMintz,Levin,Cohn,Ferris,Glovsky&Popeo,P.C.One Financial CenterBoston,Massachusetts 02111Telephone:(617)542-6000Facsimile:(617)542-2241Approximate date of commencement of proposed sale to the public:As soon as practicable after the effective date of thisR

5、egistration Statement.If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415under the Securities Act of 1933,check the following box.If this Form is filed to register additional securities for an offering pursuant to Rule 462(b)

6、under the Securities Act,checkthe following box and list the Securities Act registration statement number of the earlier effective registration statement for thesame offering.If this Form is a post-effective amendment filed pursuant to Rule 462(c)under the Securities Act,check the following boxand l